No New HIV Infections Seen Among San Francisco Kaiser PrEP Users

No new HIV infections have occurred among more than 500 Kaiser Permanente San Francisco members using pre-exposure prophylaxis -- better known as PrEP -- but condom use appears to be declining among a subset of gay men, according to a small survey presented at a December 1 forum commemorating World AIDS Day.

Read more:

Coverage of HIV Research for Prevention Conference (HIVR4P 2014)

HIVandHepatitis.com coverage of the HIV Research for Prevention Conference (HIVR4P 2014), October 28-31, in Cape Town.

This conference -- combining the previous HIV Vaccines and Microbicides meetings -- includes all aspects of HIV prevention including experimental vaccines, microbicide gels and rings, and pre-exposure prophylaxis (PrEP).

Full listing of coverage by topic

HIVR4P 2014 website

11/4/14

HIV Drug Therapy: Truvada PrEP Use Rising, Especially Among Men

The number of people using Truvada for pre-exposure prophylaxis (PrEP) in the U.S. is increasing, and a growing proportion of users are men, according to an analysis of data from approximately half of American pharmacies presented this week at the HIV Drug Therapy 2014 conference in Glasgow.

Read more:

HIVR4P 2014: Injectable Cabotegravir Makes Progress, Doubts About Injectable Rilpivirine

Researchers have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir (formerly GSK1256744) that will be taken into efficacy trials to see if it can be used for pre-exposure prophylaxis (PrEP). Progress on an injectable formulation of another drug, rilpivirine, received a setback, however, when animal studies showed it lost its efficacy against viral challenge after only 18-21 days, researchers reported at the HIV Research for Prevention meeting this week in Cape Town.

Read more: